BG61713B1 - Стабилен ретиноиден състав за локално приложение - Google Patents
Стабилен ретиноиден състав за локално приложение Download PDFInfo
- Publication number
- BG61713B1 BG61713B1 BG100267A BG10026795A BG61713B1 BG 61713 B1 BG61713 B1 BG 61713B1 BG 100267 A BG100267 A BG 100267A BG 10026795 A BG10026795 A BG 10026795A BG 61713 B1 BG61713 B1 BG 61713B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- polyoxyethylene
- composition according
- retinoid
- composition
- ionic surfactant
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 150000004492 retinoid derivatives Chemical class 0.000 title claims description 18
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 15
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 4
- -1 polyoxyethylene Polymers 0.000 claims description 29
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 17
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims description 4
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 claims description 4
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 3
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 150000004682 monohydrates Chemical group 0.000 claims description 2
- 229940117972 triolein Drugs 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 1
- 229960002227 clindamycin Drugs 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 abstract description 8
- 239000002253 acid Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 206010000496 acne Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000002874 Acne Vulgaris Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 4
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 4
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 4
- 229960002303 citric acid monohydrate Drugs 0.000 description 4
- 229960002291 clindamycin phosphate Drugs 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229960000281 trometamol Drugs 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229920002884 Laureth 4 Polymers 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940061515 laureth-4 Drugs 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 229940127555 combination product Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/90—Block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP93201931 | 1993-07-01 | ||
| PCT/NL1994/000151 WO1995001160A1 (en) | 1993-07-01 | 1994-07-01 | Stable topical retinoid compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG100267A BG100267A (bg) | 1996-07-31 |
| BG61713B1 true BG61713B1 (bg) | 1998-04-30 |
Family
ID=8213946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG100267A BG61713B1 (bg) | 1993-07-01 | 1995-12-29 | Стабилен ретиноиден състав за локално приложение |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5690923A (da) |
| EP (1) | EP0706370B2 (da) |
| JP (2) | JP3947215B2 (da) |
| AT (1) | ATE202694T1 (da) |
| AU (1) | AU678039B2 (da) |
| BG (1) | BG61713B1 (da) |
| CA (1) | CA2166062C (da) |
| CZ (1) | CZ285679B6 (da) |
| DE (1) | DE69427639T3 (da) |
| DK (1) | DK0706370T4 (da) |
| ES (1) | ES2160631T5 (da) |
| FI (1) | FI115607B (da) |
| GR (1) | GR3036761T3 (da) |
| HU (1) | HU217869B (da) |
| MD (1) | MD1587C2 (da) |
| NO (1) | NO311066B1 (da) |
| PT (1) | PT706370E (da) |
| RO (1) | RO115109B1 (da) |
| RU (1) | RU2134101C1 (da) |
| SI (1) | SI0706370T2 (da) |
| SK (1) | SK279919B6 (da) |
| UA (1) | UA41937C2 (da) |
| WO (1) | WO1995001160A1 (da) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE202694T1 (de) * | 1993-07-01 | 2001-07-15 | Yamanouchi Europ Bv | Retinoid enthaltende stabile topische zusammensetzungen |
| WO1998018492A1 (fr) * | 1996-10-25 | 1998-05-07 | Yoshitomi Pharmaceutical Industries Ltd. | Procede pour empecher la precipitation de medicaments |
| DE19903729A1 (de) * | 1999-01-30 | 2000-08-03 | Beiersdorf Ag | Verwendung von oberflächenaktiven Citronensäureestern zur Stabilisierung von Retinoiden, synergistische Gemische aus Retinoiden und oberflächenaktiven Substanzen sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen |
| CA2382214A1 (en) * | 1999-08-20 | 2001-03-01 | Unilever Plc | Skin cosmetic compositions for reducing skin irritation from weak carboxylic acids |
| DE10025756C2 (de) * | 2000-05-25 | 2003-02-20 | Cognis Deutschland Gmbh | Lösungsvermittler |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| US7060732B2 (en) * | 2000-12-12 | 2006-06-13 | Imaginative Research Associates, Inc. | Antibiotic/benzoyl peroxide dispenser |
| US20060189552A1 (en) * | 2000-12-12 | 2006-08-24 | Mohan Vishnupad | Dispenser for dispensing three or more actives |
| US20110142922A1 (en) * | 2002-04-30 | 2011-06-16 | Ferndale Ip, Inc. | Stabilized composition and method for dermatological treatment |
| US20030215493A1 (en) * | 2002-04-30 | 2003-11-20 | Patel Pravin M. | Composition and method for dermatological treatment |
| US7939489B2 (en) * | 2002-12-23 | 2011-05-10 | Avon Products, Inc. | Oil absorbent topical compositions and methods for using same |
| NZ541526A (en) * | 2003-01-24 | 2008-03-28 | Stiefel Res Australia Pty Ltd | Clindamycin phosphate foam |
| US7662855B2 (en) * | 2004-05-11 | 2010-02-16 | Imaginative Research Associates, Inc. | Retinoid solutions and formulations made therefrom |
| US20060014834A1 (en) * | 2004-05-11 | 2006-01-19 | Mohan Vishnupad | Retinoid solutions and formulations made therefrom |
| DE602005021238D1 (de) * | 2004-11-09 | 2010-06-24 | Imaginative Res Associates Inc | Retinoidlösungen und formulierungen daraus |
| AU2005306397A1 (en) * | 2004-11-19 | 2006-05-26 | Aventis Pharmaceuticals Inc. | Antibiotic compounds, compositions and medical uses |
| WO2006089070A2 (en) * | 2005-02-17 | 2006-08-24 | Connetics Corporation | Acne gel |
| AR054805A1 (es) * | 2005-06-29 | 2007-07-18 | Stiefel Laboratories | Composiciones topicas para el tratamiento de la piel |
| US9107844B2 (en) * | 2006-02-03 | 2015-08-18 | Stiefel Laboratories Inc. | Topical skin treating compositions |
| PL2005958T3 (pl) * | 2006-03-08 | 2013-11-29 | Nihon Nohyaku Co Ltd | Kompozycja farmaceutyczna do stosowania zewnętrznego |
| JP5184341B2 (ja) * | 2006-03-08 | 2013-04-17 | 日本農薬株式会社 | 外用の医薬組成物 |
| PL2206494T3 (pl) | 2006-03-31 | 2016-06-30 | Stiefel Res Australia Pty Ltd | Spienialny żel zawiesinowy |
| US20080287373A1 (en) * | 2007-05-17 | 2008-11-20 | Popp Karl F | Topical skin treating kits |
| EP2170254A2 (en) * | 2007-06-21 | 2010-04-07 | Dow Global Technologies Inc. | Stabilizers for hydrophobic components in personal care compositions |
| US20100204293A1 (en) * | 2007-09-05 | 2010-08-12 | Pola Pharma Inc. | Pharmaceutical composition |
| KR20100075476A (ko) * | 2007-09-05 | 2010-07-02 | 가부시키가이샤 폴라 파마 | 항진균 조성물 |
| EP2191828B1 (en) * | 2007-09-05 | 2016-08-10 | Pola Pharma Inc. | Antifungal pharmaceutical composition |
| JP2011500687A (ja) * | 2007-10-18 | 2011-01-06 | メディシス・ファーマシューティカル・コーポレーション | 水性レチノイドおよび過酸化ベンゾイルゲル |
| FR2939683B1 (fr) * | 2008-12-17 | 2012-04-20 | Oreal | Composition cosmetique comprenant un polyester sulfonique ramifie et un tensioactif particulier et utilisations en coiffage |
| JP5688405B2 (ja) | 2009-04-09 | 2015-03-25 | 株式会社ポーラファルマ | 抗真菌医薬組成物 |
| KR101409792B1 (ko) | 2009-04-09 | 2014-06-19 | 니혼노야쿠가부시키가이샤 | 항진균성 약제학적 조성물 |
| WO2011024620A1 (en) | 2009-08-25 | 2011-03-03 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
| US11071878B2 (en) * | 2009-12-31 | 2021-07-27 | Sol-Gel Technologies Ltd. | Core stabilized microcapsules, method of their preparation and uses thereof |
| BR112013031813A2 (pt) | 2011-06-29 | 2016-12-13 | Sol Gel Technologies Ltd | composição para aplicação tópica |
| JP5865624B2 (ja) * | 2011-08-01 | 2016-02-17 | 昭和電工株式会社 | 皮膚外用剤およびその製造方法 |
| JP5865623B2 (ja) * | 2011-08-01 | 2016-02-17 | 昭和電工株式会社 | 皮膚外用剤およびその製造方法 |
| FR2991175B1 (fr) * | 2012-06-01 | 2014-12-19 | Galderma Res & Dev | Compositions pharmaceutiques topiques de type emulsion h/e contenant un retinoide |
| MD4479C1 (ro) * | 2015-02-12 | 2017-12-31 | Валериу НИКУШОР | Compoziţie de erbicide şi procedeu de combatere a buruienilor şi ierburilor în culturile de sfeclă de zahăr cu utilizarea acesteia |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4532133A (en) * | 1983-05-24 | 1985-07-30 | Basf Wyandotte Corporation | Low temperature stable, emulsifiable vitamin A concentrates |
| FR2591105B1 (fr) * | 1985-12-11 | 1989-03-24 | Moet Hennessy Rech | Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide. |
| GB8821129D0 (en) * | 1988-09-09 | 1988-10-12 | Unilever Plc | Cosmetic composition |
| MY105521A (en) * | 1989-04-17 | 1994-10-31 | Healthpoint Ltd | Moisturizing vehicle for topical application of vitamin a acid. |
| CA2063576C (en) * | 1989-06-07 | 1994-01-25 | Gail S. Bazzano | Slow release vehicles for minimizing skin irritancy of topical compositions |
| JP2827295B2 (ja) * | 1989-07-04 | 1998-11-25 | 大正製薬株式会社 | ビタミンａ類含有点眼剤 |
| FI903483A0 (fi) † | 1989-07-13 | 1990-07-10 | Bristol Myers Squibb Co | Tretinoin innehaollande stabila emulsionskraemformulationer. |
| US5043356A (en) * | 1990-01-19 | 1991-08-27 | Fulton Jr James E | Composition and method for rejuvenating skin using vitamin A propionate |
| JP3031990B2 (ja) * | 1990-10-19 | 2000-04-10 | 同仁医薬化工株式会社 | 消炎鎮痛クリーム剤組成物 |
| ATE202694T1 (de) * | 1993-07-01 | 2001-07-15 | Yamanouchi Europ Bv | Retinoid enthaltende stabile topische zusammensetzungen |
-
1994
- 1994-07-01 AT AT94923832T patent/ATE202694T1/de active
- 1994-07-01 RO RO95-02287A patent/RO115109B1/ro unknown
- 1994-07-01 DK DK94923832T patent/DK0706370T4/da active
- 1994-07-01 PT PT94923832T patent/PT706370E/pt unknown
- 1994-07-01 SK SK1597-95A patent/SK279919B6/sk not_active IP Right Cessation
- 1994-07-01 EP EP94923832A patent/EP0706370B2/en not_active Expired - Lifetime
- 1994-07-01 JP JP50341495A patent/JP3947215B2/ja not_active Expired - Lifetime
- 1994-07-01 CA CA002166062A patent/CA2166062C/en not_active Expired - Lifetime
- 1994-07-01 RU RU96102009/14A patent/RU2134101C1/ru active
- 1994-07-01 CZ CZ953483A patent/CZ285679B6/cs not_active IP Right Cessation
- 1994-07-01 AU AU73913/94A patent/AU678039B2/en not_active Expired
- 1994-07-01 ES ES94923832T patent/ES2160631T5/es not_active Expired - Lifetime
- 1994-07-01 UA UA95125456A patent/UA41937C2/uk unknown
- 1994-07-01 MD MD95-0443A patent/MD1587C2/ro not_active IP Right Cessation
- 1994-07-01 WO PCT/NL1994/000151 patent/WO1995001160A1/en active IP Right Grant
- 1994-07-01 SI SI9430382T patent/SI0706370T2/xx unknown
- 1994-07-01 US US08/571,898 patent/US5690923A/en not_active Expired - Lifetime
- 1994-07-01 DE DE69427639T patent/DE69427639T3/de not_active Expired - Lifetime
- 1994-07-01 HU HU9503721A patent/HU217869B/hu unknown
-
1995
- 1995-12-20 NO NO19955193A patent/NO311066B1/no not_active IP Right Cessation
- 1995-12-22 FI FI956204A patent/FI115607B/fi not_active IP Right Cessation
- 1995-12-29 BG BG100267A patent/BG61713B1/bg unknown
-
2001
- 2001-09-28 GR GR20010401618T patent/GR3036761T3/el unknown
-
2006
- 2006-09-13 JP JP2006248175A patent/JP2006328089A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG61713B1 (bg) | Стабилен ретиноиден състав за локално приложение | |
| USRE41134E1 (en) | Slow release vehicles for minimizing skin irritancy of topical compositions | |
| KR101455038B1 (ko) | 하나 이상의 레티노이드 및 벤조일 퍼옥시드를 포함하는 유화액 | |
| AU633892B2 (en) | Moisturizing vehicle for topical application of vitamin a acid | |
| US4621075A (en) | Gel-form topical antibiotic compositions | |
| JPH01311014A (ja) | 抗菌性皮膚外用剤 | |
| KR950003611B1 (ko) | 항진균 외용 이미다졸 제제 | |
| EP0603405A1 (en) | Composition for treating acne vulgaris | |
| JP3313148B2 (ja) | 皮膚外用剤 | |
| JP3258801B2 (ja) | 皮膚新陳代謝促進剤 | |
| JP3280712B2 (ja) | 皮膚外用剤 | |
| JP3455553B2 (ja) | 皮膚外用剤 | |
| WO2022140467A1 (en) | Topical compositions and methods of treating skin diseases and conditions with such compositions | |
| CA2156396A1 (en) | Stable dermatologic preparation containing mycophenolic acid | |
| BG105093A (bg) | Фармацевтичен състав на база на еритромицинови соли на мастни киселини за топично третиране на кожни заболявания | |
| CS234469B1 (cs) | Dermální přípravek s obsahem kyseliny vitaminu A | |
| CZ20004496A3 (cs) | Farmaceutická kompozice na bázi erythromycinu ve formě soli mastné kyseliny obsahující ve zbytku mastné kyseliny 12 až 22 uhlíkových atomů a použití erythromycinu ve formě této soli k topickému léčení kožních nemocí | |
| JPH0632719A (ja) | 皮膚外用剤 | |
| KR19980074477A (ko) | 폴리옥시에틸렌알킬에테르를 기제성분으로 함유하는 비스테로이드계 소염진통제 |